At a glance

c-LEcta is a global biotechnology company specializing in the development, production and distribution of enzyme products. The company uses world-class enzyme engineering and production technologies to provide its partners in the food and pharmaceutical industries with superior biotechnological solutions for innovative industrial applications. Product development is based on the proprietary enzyme technology pwlatform ENESYZ® and is carried out both in-house and in close cooperation with industry partners worldwide. c-LEcta supplies its products to more than 400 customers in over 40 countries. c-LEcta currently employs more than 130 people at its headquarters in Leipzig, Germany. c-LEcta is part of the Kerry Group since the beginning of 2022.

Market focus

c-LEcta use best-in-class enzyme engineering and production technologies to deliver superior biotech solutions enabling innovative industrial applications for partners in food and pharma. Our vision is to develop c-LEcta into a recognized global leader for high-performance enzymes promoting human health.

The enzyme products from c-LEcta are used in many different fields, with a focus on the food and pharma industries. For example, they enable the production of active pharmaceutical substances and vaccines or can be used in the production of foods and food additives such as prebiotics or natural sweeteners. Most of the enzymes developed by c-LEcta are produced by the company itself and distributed throughout the world; a few are utilized by industry partners. Numerous innovation projects have been successfully brought to market, and many new development projects are currently under way.

c-LEcta Products for Pharma

Biotechnology expedites the journey of novel medicines, inclusive of Advanced Therapy Medicinal Products (ATMPs), from conceptualization to market availability, thereby reaching patients swiftly. These products are adept at targeting specific diseases while mitigating undesirable side effects.

Employing enzymes as biological raw materials curtails the dependency on chemical substances, engendering a more benign production of the end products.

c-LEcta’s offerings for the pharmaceutical sphere span a myriad of applications. Their enzymes are instrumental in facilitating the production of innovative therapeutic modalities, encompassing gene and cell therapy, alongside the synthesis of Active Pharmaceutical Ingredients (APIs). Their well-honed production protocols ensure the capability of manufacturing substantial quantities within a constrained timeframe.

More Details

ebiohippo.com provides biomedical researchers with a one-stop informatic shopping experience by transforming biotechnology products’ data into a ready-to-analyze state. We collect and unify suppliers’ data on a single platform to reduce the time of searching, uncertainty, and cost of scientific experiments.